SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the
U.S. Food and Drug Administration (FDA) has approved BYDUREON™ (exenatide
extended-release for injectable suspension) – the first once-weekly
treatment for type 2 diabetes. BYDUREON is a glucagon-like peptide-1 (GLP-1)
receptor agonist indicated as an adjunct to diet and exercise to improve
glycemic control in adults with type 2 diabetes in multiple clinical
settings. BYDUREON will be available in pharmacies nationwide in February.
To view the multimedia assets associated with this release, please visit:
http://www.multivu.com/mnr/53897-amylin-alkermes-plc-bydureon-fda-approved-treatment-type-2-diabetes
"With BYDUREON, U.S. physicians and patients can now choose a therapy that
offers continuous blood sugar control in ... (more)
TEL AVIV, Israel, Jan. 23, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB:
NSPR) (the "Company" or "InspireMD"), a medical device company focusing on
the development and commercialization of its proprietary stent platform
technology for use in patients with Acute Myocardial Infarctions, today
announced its business objectives for 2012 and reviewed its achievements in
2011. InspireMD stents are based on the Company's proprietary MicroNet™
platform technology.
The Company said its major objective in the next year is to leverage its
MASTER Trial results to commercialize the MGuard... (more)
CALGARY, ALBERTA -- (Marketwire) -- 01/26/12 -- Acceleware® Ltd. (TSX
VENTURE:AXE) (the "Corporation") a leading developer of high performance
computing applications, today announced announces that it has granted stock
options to acquire up to 1,380,000 common shares of the Corporation to
certain of its employees, officers and directors. The options have an
exercise price of $0.10 per common share and expire on January 26th, 2017.
One third of the options shall vest on the first anniversary of the grant
date, one third of the options shall vest on the second anniversary of the
... (more)
ABBOTT PARK, Illinois, January 25, 2012 /PRNewswire/ --
-- Fourth Quarter Ongoing EPS of $1.45, Up 11.5 Percent --
-- On Track to Separate into Two Leading Health Care Companies --
Abbott (NYSE: ABT) today announced financial results for the fourth quarter
ended Dec. 31, 2011.
Diluted earnings per share, excluding specified items, were $1.45, at the
high end of Abbott's previous guidance range, reflecting 11.5 percent growth.
Diluted earnings per share under Generally Accepted Accounting Principles
(GAAP) were $1.02, including specified items. Worldwide sales increased 4.1
percen... (more)
BETHESDA, Md., Jan. 23, 2012 /PRNewswire/ -- PinneyAssociates, Inc., a
health care consulting firm with offices in Bethesda, MD and Pittsburgh, PA,
is pleased to announce the following promotions, effective 1 January 2012:
Karen Gerlach, PhD, MPH, to Co-Director, Clinical and Behavioral Research
Lucy Owen, to Vice President, Program Operations and Over-the-Counter Switch
Mitch Zeller, JD, to Senior Vice President Joe Gitchell, to President John
Pinney, to Chief Executive Officer
"We are fortunate to have such a high-performing and effective team, and I
believe that these promotion... (more)
Subscribe to FDA News Email News Alerts
Subscribe via RSS
Ulitzer content is offered under Creative Commons "Attribution Non-Commercial No Derivatives" License.
For any reuse or distribution, you must make clear to others the license terms of this work.
The best way to do this is with a link to this web page.
Any of the above conditions can be waived if you get written permission from Ulitzer, Inc., the copyright holder.
Nothing in this license impairs or restricts the author's moral rights.